Multi-cancer early detection (MCED) blood tests in 2026: Galleri vs Cancerguard and the Future of Early Cancer Detection
Multi-cancer early detection (MCED) tests are emerging as one of the most important developments in cancer screening. Instead of screening for one cancer at a time with mammography, colonoscopy, CT scans, or other conventional tests, MCED blood tests attempt to detect biological signals associated with multiple cancers from a single blood sample. Two of the most prominent commercial MCED tests in the United States are GRAIL's Galleri® test and Exact Sciences' Cancerguard® test . Both are designed to address a major problem in modern oncology: many cancers have no recommended routine screening test and may not be diagnosed until symptoms appear or the disease has progressed. But there is an important distinction between detecting a cancer signal and proving that a screening test saves lives . As MCED technology moves into a more important phase in 2026, the central question is no longer simply: Can a blood test detect cancer? The bigger question is: Can MCED scr...